A recent Janssen/Qiagen collaboration on a CDx for bladder cancer & the test utilised by Labcorp, one of the biggest path labs in the USA & who also owns Covance, a very large global clinical trial company.
If PromarkerD was to become a CDx for Canafliglozin (Invokana), it will be a far more common & utilised test than the one above for Bladder Ca. It’s well worth a look into if Investors haven’t already.
PIQ Price at posting:
46.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)